0.01Open0.05Pre Close1 Volume118 Open Interest59.00Strike Price1.00Turnover6045.99%IV25.47%PremiumDec 13, 2024Expiry Date0.00Intrinsic Value100Multiplier-1DDays to Expiry0.01Extrinsic Value100Contract SizeAmericanOptions Type0.0073Delta0.0047Gamma4703.00Leverage Ratio-45.4446Theta0.0000Rho34.32Eff Leverage0.0000Vega
Viking Therapeutics Stock Discussion
loading...
I suspect they chose not to present the full safety profile, given that the weight loss results for the 120 mg and 280 mg QM cohorts, in obese non-diabetics (without dose escalations), at week 16 in P2 are consistent with the P1 results (see slide 1). So, it is likely that the 120 mg and 280 mg QM (without dose...
No comment yet